Overview

This study aims to evaluate the pathophysiological aspects of the role of inflammation and gut microbiota in mood disorders, in particular in depression, and their therapeutic implications on a cohort of the Lebanese population. Specific objective: The evaluation of probiotic intake (CEREBIOME®, Lallemand Health Solutions Inc., Mirabel, Canada) on depressive patients and the inflammatory state. Evaluate the effect of oral intake of a probiotic agent, on clinical and plasma inflammatory markers, in a subgroup of target patients versus a subgroup treated with placebo, in combination with conventional treatment.

Eligibility

Inclusion Criteria:

• Major depressive disorder: current depressive episode according to MINI (DSM-5) with a MADRS score of ≥ 20
• Males and females between ages 18 and 65
• Able to understand and comply with the requirements of the study
• Provision of written informed consent

Exclusion Criteria:

• Patients under anti-inflammatory drugs
• Patients under immuno-suppressants
• Use of any type of laxative
• Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
• Bipolar, schizophrenia, and addiction disorders
• Any antibiotic therapy in the past 4 weeks